For ac­count­ing pur­pos­es, Bio­gen says its $223M in­ven­to­ry of Aduhelm is ba­si­cal­ly worth­less

The bat­tle over whether Bio­gen’s Alzheimer’s drug Aduhelm ac­tu­al­ly helps pa­tients may nev­er end, but in a re­cent SEC fil­ing, Bio­gen, at least for ac­count­ing pur­pos­es, now says its $230 mil­lion stash of Aduhelm should be con­sid­ered worth­less.

In ad­di­tion to scrap­ping the en­tire com­mer­cial in­fra­struc­ture around sell­ing Aduhelm, and lay­ing off more than 1,000 in the process, the big biotech said in an SEC fil­ing yes­ter­day evening, “As of June 30, 2022, our to­tal ADUHELM in­ven­to­ry was de min­imis. As of De­cem­ber 31, 2021, we had ap­prox­i­mate­ly $223.0 mil­lion of ADUHELM in­ven­to­ry.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER